Want to see HK:9939 full AI Analyst Report?
9939 Stock Chart & Stats
HK$1.92
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$1.92
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.66 - HK$4.70
Previous CloseN/A
Volume545.00K
Average Volume (3M)4.99M
Market Cap
HK$943.58M
Enterprise ValueHK$977.46M
Total Cash (Recent Filing)HK$34.78M
Total Debt (Recent Filing)HK$86.64M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding498,660,100
10 Day Avg. Volume2,605,850
30 Day Avg. Volume4,990,601
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.33
Price to Sales (P/S)24.23
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound (2025)A material revenue rebound in 2025 indicates improving commercial traction or milestone-driven receipts, creating a potential inflection for scaled operations. If sustained, higher top-line supports operational leverage, reduces external funding dependence and improves runway over the next 2–6 months.
Moderate LeverageDebt levels around 0.45–0.55 D/E are modest for a biotech and provide structural flexibility. Moderate leverage lowers fixed financial burden, preserving borrowing capacity and options for non-dilutive financings or strategic partnerships during a multi-quarter development cycle.
Diversified Small-molecule PipelineA diversified small-molecule pipeline across multiple disease areas creates multiple value drivers and lowers binary risk from any single program. This ‘shots-on-goal’ structure supports licensing, partnership or milestone revenue potential and underpins medium-term upside beyond immediate financials.
Bears Say
Negative Gross ProfitSustained negative gross profit means core product economics are unprofitable, so scaling revenue alone may not restore profitability without structural changes. Long-term margin sustainability requires improved cost of goods, pricing power, or different product mix to achieve durable operating leverage.
Persistent Negative Cash FlowConsistent operating and free cash flow deficits imply ongoing cash burn and reliance on external capital. Over multiple quarters this raises dilution and refinancing risk, limits the ability to fund R&D internally, and can slow development timelines if access to capital tightens.
Shrinking Assets And EquityMaterial declines in assets and shareholders' equity reflect value erosion from repeated losses. A shrinking equity base reduces financial resilience, weakens credit capacity, and leaves less buffer against adverse outcomes, increasing the company’s vulnerability over the medium term.
Kintor Pharmaceutical Ltd News
9939 FAQ
What was Kintor Pharmaceutical Ltd’s price range in the past 12 months?
Kintor Pharmaceutical Ltd lowest stock price was HK$1.66 and its highest was HK$4.70 in the past 12 months.
What is Kintor Pharmaceutical Ltd’s market cap?
Kintor Pharmaceutical Ltd’s market cap is HK$943.58M.
When is Kintor Pharmaceutical Ltd’s upcoming earnings report date?
Kintor Pharmaceutical Ltd’s upcoming earnings report date is Aug 31, 2026 which is in 51 days.
How were Kintor Pharmaceutical Ltd’s earnings last quarter?
Kintor Pharmaceutical Ltd released its earnings results on Mar 30, 2026. The company reported -HK$0.277 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.277.
Is Kintor Pharmaceutical Ltd overvalued?
According to Wall Street analysts Kintor Pharmaceutical Ltd’s price is currently Overvalued.
Does Kintor Pharmaceutical Ltd pay dividends?
Kintor Pharmaceutical Ltd does not currently pay dividends.
What is Kintor Pharmaceutical Ltd’s EPS estimate?
Kintor Pharmaceutical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kintor Pharmaceutical Ltd have?
Kintor Pharmaceutical Ltd has 498,660,100 shares outstanding.
What happened to Kintor Pharmaceutical Ltd’s price movement after its last earnings report?
Kintor Pharmaceutical Ltd reported an EPS of -HK$0.277 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.216%.
Which hedge fund is a major shareholder of Kintor Pharmaceutical Ltd?
Currently, no hedge funds are holding shares in HK:9939
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kintor Pharmaceutical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.57%
12-Months-Change
Fundamentals
Return on Equity
-98.56%
Trailing 12-Months
Asset Growth
-30.76%
Trailing 12-Months
Company Description
Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
3D Medicines, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---